Company Filing History:
Years Active: 2019-2022
Title: Innovations of Jeffrey Ding in Inhalable Insulin Technology
Introduction
Jeffrey Ding is an accomplished inventor based in Rancho Cucamonga, CA, with a focus on developing high-purity inhalable insulin products. He holds a total of four patents, showcasing his significant contributions to the pharmaceutical field, particularly in diabetes management.
Latest Patents
Ding's latest patents include the development of high-purity inhalable particles of insulin and insulin analogues, along with high-efficiency methods for manufacturing these products. The inhalable insulin material is designed for pulmonary pharmaceutical applications and features insulin particles with a micrometer-level size. Key characteristics of this material include a purity of not less than 96% on a dried basis, a total amount of insulin-related impurities not exceeding 2%, and solvent impurities limited to 0.03%. Furthermore, up to 99% by volume of the insulin particles have a size of less than 5 micrometers. The high-efficiency method developed by Ding achieves a yield rate of 75 to 85% or more, marking a significant advancement in the production of inhalable insulin.
Career Highlights
Throughout his career, Jeffrey Ding has worked with notable companies, including Amphastar Pharmaceuticals, Inc. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovations and contribute to the development of cutting-edge medical products.
Collaborations
Ding has collaborated with talented individuals such as Aili Bo and Mary Ziping Luo, enhancing the collaborative efforts in his research and development projects.
Conclusion
Jeffrey Ding's innovative work in the field of inhalable insulin technology represents a significant advancement in diabetes treatment. His patents and career achievements highlight his dedication to improving patient outcomes through pharmaceutical innovation.